| 2026-11-19, 12:03 |
|
|
Ypsomed generated CHF 286.6 million in revenue from injection systems for self-administered medications in the first half of fiscal 2026/27, up 17.5 percent from the same period a year earlier. According to its November 11, 2026 ad hoc announcement, the segment’s operating profit (EBIT) rose 16.8 percent to CHF 102.3 million. The EBIT margin was 35.7 percent, down from 35.9 percent a year earlier. The company won 30 new customer projects, a third of them with new customers. Group revenue fell from CHF 362.7 million to CHF 317.6 million following the sale of the Diabetes Care business and the Ypsotec subsidiary. Group EBIT declined from CHF 151.7 million to CHF 99.8 million. Ypsomed said the prior-year figure included a one-off gain of CHF 74.6 million from divestitures. According to the half-year report, net profit fell 38.5 percent from CHF 139.1 million to CHF 85.5 million. Ypsomed invested CHF 129.7 million in property, plant and equipment during the first half, mainly to expand production capacity. The first phase of modernization in Solothurn is complete. The second plant in Schwerin is scheduled to open in 2027. Production is ramping up in Changzhou, China, and Ypsomed is building its first U.S. plant in Holly Springs, North Carolina. For the full 2026/27 fiscal year, Ypsomed now expects revenue in its injection systems segment to grow by 13 to 16 percent, up from its previous forecast of 12 to 15 percent. The company raised its EBIT forecast for the segment from CHF 210–230 million to CHF 220–240 million. More information: www.ypsomed.com |
Ypsomed AG, Burgdorf, Schweiz
Flux LTD
34788 İstanbul, Turkey
technotrans solutions GmbH
58540 Meinerzhagen, Germany
EUROPLAST GmbH
9772 Dellach, Austria
Ecoyadi-2 Sp. Z o.o.
54-215 Wroclaw, Poland
PolyTALENT GmbH
49393 Lohne, Germany